Ann: Cynata Therapeutics GvHD Clinical Trial & Corporate Progress, page-49

First 49 Last

Share
Profile

Follow
Wyman Wells

315 Posts.

28/06/17

12:53

Post #: 25538190
Share

Thanks for sharing your thoughts

Originally posted by bpinvestnstocks ↑

"Does CYP have a single point of failure like IIL?"

I don't know.  Looking for single points of failure requires research time and energy as well as a mindset. I do know cell and molecular biology is not close to being fully understood by cell and molecular biologists yet. We cannot build a cell from scratch. The origins of life remain largely mysterious.

1)  The original induced pluripotent stem cell came from someone somewhere. Any unknown problems in that cell would have been duplicated. iPSC technology isn't that old - longitudinal data can't be that available. That original cell might have characteristics (genes including oncogenes) that make it more favorable in some patients than others.

A better starter iPSC might still be produced. Perhaps CRISPR/Cas9 will be used to produce a better starter iPSC cell.

2) A successful patent challenge.

3) Better technology (a better platform) may become apparent with further discoveries in cell and molecular biology. And/or with further work being done is cell biology culturing at commercial scale. The field of culturing cells at commercial scale is not old, there has not been a need for it.

4) Governments may ignore or revoke patents.   Voters don't like being denied medicines or having them priced out of their reach.

Fuji hasn't exercised its option yet. Maybe they see some sense in waiting for more data - like the end of the trial (not that far away until more data is available) before increasing their exposure.

I don't think ILL and SRX were schmucks. Cellular and molecular biology are just harder than many non cellular and molecular biologists appreciate - the models presented - even of dysfunctional systems are based only on what is currently known so real systems can have complexity that is as yet undiscovered. Cells are small (hard to examine) and living (dynamic and subject to adaption and evolution - eg. cancers) so progress in understanding systems of cells isn't as easy as non-experts may imagine.

Plus - when it comes to things that hold out hope for people who are sick or who know people who are sick - people are even less objective than normal.

Expand

CYP Price at posting: 57.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

The Rising Tide: How institutional adoption is shaping the future of crypto

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

WHC

Whitehaven to sell 30% of Blackwater coal mine to Japanese JV partners

STK

Strickland Metals jumps on mammoth gold-copper-silver hit over 300m width at Serbian Rogozna Project

CU6

US FDA awards Clarity Pharma's novel prostate cancer PET scan imaging compound fast track status

There are more pages in this discussion • 1 more message in this thread...

First 49 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 21.0¢		Change 0.000(0.00%)		Mkt cap ! $37.91M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
7	238301	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	15000	1

View Market Depth

No.	Vol.	Price($)
7	238301	0.200
2	68825	0.195
2	25789	0.190
2	5055	0.180
3	7139	0.175

Price($)	Vol.	No.
0.210	15000	1
0.225	11225	2
0.230	161397	3
0.240	10000	1
0.255	192726	2

Last trade - 11.10am 22/08/2024 (20 minute delay)

CYP (ASX) Chart

Day chart unavailable

Ann: Cynata Therapeutics GvHD Clinical Trial & Corporate Progress, page-49

The Rising Tide: How institutional adoption is shaping the future of crypto

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Whitehaven to sell 30% of Blackwater coal mine to Japanese JV partners

Strickland Metals jumps on mammoth gold-copper-silver hit over 300m width at Serbian Rogozna Project

US FDA awards Clarity Pharma's novel prostate cancer PET scan imaging compound fast track status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Cynata Therapeutics GvHD Clinical Trial & Corporate Progress, page-49

Top Stories

The Rising Tide: How institutional adoption is shaping the future of crypto

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Whitehaven to sell 30% of Blackwater coal mine to Japanese JV partners

Strickland Metals jumps on mammoth gold-copper-silver hit over 300m width at Serbian Rogozna Project

US FDA awards Clarity Pharma's novel prostate cancer PET scan imaging compound fast track status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News